Cloning MET Inhibitor

Capmatinib is a MET inhibitor. It’s super selective. It is designed to target and inhibit MET kinase, which plays a key role in tumor growth, It’s especially good at targeting that type of lung cancer – NSCLC – with a specific gene mutation.

You can get it in 150 mg or 200 mg doses, but usually you take 400 mg twice a day. You can take it with or without food. It comes in pill form, each bottle has 60 tablets.

The therapeutic approach is focused on managing and treating NSCLC by selectively blocking MET signaling, thereby limiting tumor progression and associated metastasis.